Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Frontiers in pigment cell and melanoma research.

Filipp FV, Birlea S, Bosenberg MW, Brash D, Cassidy PB, Chen S, D'Orazio JA, Fujita M, Goh BK, Herlyn M, Indra AK, Larue L, Leachman SA, Le Poole C, Liu-Smith F, Manga P, Montoliu L, Norris DA, Shellman Y, Smalley KSM, Spritz RA, Sturm RA, Swetter SM, Terzian T, Wakamatsu K, Weber JS, Box NF.

Pigment Cell Melanoma Res. 2018 Nov;31(6):728-735. doi: 10.1111/pcmr.12728. Epub 2018 Oct 3.

2.

BH3 mimetics induce apoptosis independent of DRP-1 in melanoma.

Mukherjee N, Strosnider A, Vagher B, Lambert KA, Slaven S, Robinson WA, Amato CM, Couts KL, Bemis JGT, Turner JA, Norris DA, Shellman YG.

Cell Death Dis. 2018 Sep 5;9(9):907. doi: 10.1038/s41419-018-0932-z.

3.

ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.

Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, Shellman YG, Rioth MJ, Tan AC, Gonzalez R, Medina T, Doebele RC, Robinson WA.

Mol Cancer Ther. 2018 Jan;17(1):222-231. doi: 10.1158/1535-7163.MCT-17-0472. Epub 2017 Oct 20.

4.

Repigmentation of Human Vitiligo Skin by NBUVB Is Controlled by Transcription of GLI1 and Activation of the β-Catenin Pathway in the Hair Follicle Bulge Stem Cells.

Goldstein NB, Koster MI, Jones KL, Gao B, Hoaglin LG, Robinson SE, Wright MJ, Birlea SI, Luman A, Lambert KA, Shellman YG, Fujita M, Robinson WA, Roop DR, Norris DA, Birlea SA.

J Invest Dermatol. 2018 Mar;138(3):657-668. doi: 10.1016/j.jid.2017.09.040. Epub 2017 Oct 17.

5.

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.

Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, Lewis KD, Tentler JJ, Tan AC, Robinson WA.

Melanoma Res. 2017 Jun;27(3):189-199. doi: 10.1097/CMR.0000000000000345.

6.

NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma.

Zhai Z, Liu W, Kaur M, Luo Y, Domenico J, Samson JM, Shellman YG, Norris DA, Dinarello CA, Spritz RA, Fujita M.

Oncogene. 2017 Jul 6;36(27):3820-3830. doi: 10.1038/onc.2017.26. Epub 2017 Mar 6.

7.

Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.

Mukherjee N, Almeida A, Partyka KA, Lu Y, Schwan JV, Lambert K, Rogers M, Robinson WA, Robinson SE, Applegate AJ, Amato CM, Luo Y, Fujita M, Norris DA, Shellman YG.

Oncotarget. 2016 Dec 20;7(51):84594-84607. doi: 10.18632/oncotarget.13141.

8.

Maternal anti-HBVs suppress the immune response of infants to hepatitis B vaccine.

Chen X, Gui X, Zhang L, Huang F, Zhong H, Pang Z, Wang S, Tang L, Fu L, Peng Y, Shellman Y.

J Viral Hepat. 2016 Dec;23(12):955-960. doi: 10.1111/jvh.12572. Epub 2016 Jul 29.

PMID:
27469237
9.

Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells.

Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG.

Oncotarget. 2017 Jul 18;8(29):46801-46817. doi: 10.18632/oncotarget.8695.

10.

IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.

Hintzsche J, Kim J, Yadav V, Amato C, Robinson SE, Seelenfreund E, Shellman Y, Wisell J, Applegate A, McCarter M, Box N, Tentler J, De S, Robinson WA, Tan AC.

J Am Med Inform Assoc. 2016 Jul;23(4):721-30. doi: 10.1093/jamia/ocw022. Epub 2016 Mar 28.

11.

SASH1 Is Involved in an Autosomal Dominant Lentiginous Phenotype.

Shellman YG, Lambert KA, Brauweiler A, Fain P, Spritz RA, Martini M, Janssen KP, Box NF, Terzian T, Rewers M, Horvath A, Stratakis CA, Robinson WA, Robinson SE, Norris DA, Artinger KB, Pacheco TR.

J Invest Dermatol. 2015 Dec;135(12):3192-3194. doi: 10.1038/jid.2015.292. Epub 2015 Jul 23. No abstract available.

12.

Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells.

Mukherjee N, Schwan JV, Fujita M, Norris DA, Shellman YG.

J Invest Dermatol. 2015 Sep;135(9):2155-2161. doi: 10.1038/jid.2015.145. Epub 2015 May 7. Review.

13.

Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells.

Mukherjee N, Reuland SN, Lu Y, Luo Y, Lambert K, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG.

J Invest Dermatol. 2015 Mar;135(3):842-850. doi: 10.1038/jid.2014.464. Epub 2014 Oct 28.

14.

miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma.

Bennett PE, Bemis L, Norris DA, Shellman YG.

Physiol Genomics. 2013 Nov 15;45(22):1049-59. doi: 10.1152/physiolgenomics.00116.2013. Epub 2013 Sep 17. Review.

15.

Biphasic pro-melanogenic and pro-apoptotic effects of all-trans-retinoic acid (ATRA) on human melanocytes: time-course study.

Baldea I, Costin GE, Shellman Y, Kechris K, Olteanu ED, Filip A, Cosgarea MR, Norris DA, Birlea SA.

J Dermatol Sci. 2013 Nov;72(2):168-76. doi: 10.1016/j.jdermsci.2013.06.004. Epub 2013 Jun 21.

PMID:
23867358
16.

CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1.

Deng H, Liu J, Deng Y, Han G, Shellman YG, Robinson SE, Tentler JJ, Robinson WA, Norris DA, Wang XJ, Zhang Q.

J Invest Dermatol. 2013 May;133(5):1294-301. doi: 10.1038/jid.2012.487. Epub 2013 Jan 10.

17.

ABT-737 synergizes with Bortezomib to kill melanoma cells.

Reuland SN, Goldstein NB, Partyka KA, Smith S, Luo Y, Fujita M, Gonzalez R, Lewis K, Norris DA, Shellman YG.

Biol Open. 2012 Feb 15;1(2):92-100. doi: 10.1242/bio.2011035. Epub 2011 Nov 16.

18.

MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD).

Reuland SN, Smith SM, Bemis LT, Goldstein NB, Almeida AR, Partyka KA, Marquez VE, Zhang Q, Norris DA, Shellman YG.

J Invest Dermatol. 2013 May;133(5):1286-93. doi: 10.1038/jid.2012.400. Epub 2012 Nov 29.

19.

A simple protocol for using a LDH-based cytotoxicity assay to assess the effects of death and growth inhibition at the same time.

Smith SM, Wunder MB, Norris DA, Shellman YG.

PLoS One. 2011;6(11):e26908. doi: 10.1371/journal.pone.0026908. Epub 2011 Nov 17.

20.

The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.

Reuland SN, Goldstein NB, Partyka KA, Cooper DA, Fujita M, Norris DA, Shellman YG.

PLoS One. 2011;6(8):e24294. doi: 10.1371/journal.pone.0024294. Epub 2011 Aug 29.

21.

Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma.

Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita M.

Gene Ther. 2011 Aug;18(8):827-34. doi: 10.1038/gt.2011.28. Epub 2011 Mar 10.

22.

A mediator of Rho-dependent invasion moonlights as a methionine salvage enzyme.

Kabuyama Y, Litman ES, Templeton PD, Metzner SI, Witze ES, Argast GM, Langer SJ, Polvinen K, Shellman Y, Chan D, Shabb JB, Fitzpatrick JE, Resing KA, Sousa MC, Ahn NG.

Mol Cell Proteomics. 2009 Oct;8(10):2308-20. doi: 10.1074/mcp.M900178-MCP200. Epub 2009 Jul 20.

23.

BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.

Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, Shellman YG.

J Invest Dermatol. 2009 Apr;129(4):964-71. doi: 10.1038/jid.2008.327. Epub 2008 Nov 6.

24.

Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in melanocytic cells.

Goldstein NB, Johannes WU, Gadeliya AV, Green MR, Fujita M, Norris DA, Shellman YG.

J Invest Dermatol. 2009 Feb;129(2):432-7. doi: 10.1038/jid.2008.227. Epub 2008 Jul 31.

25.

MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines.

Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG, Erickson PF, Shellman YG, Robinson WA.

Cancer Res. 2008 Mar 1;68(5):1362-8. doi: 10.1158/0008-5472.CAN-07-2912.

26.

Photoprotective effects of bucillamine against UV-induced damage in an SKH-1 hairless mouse model.

Anwar A, Gu M, Brady S, Qamar L, Behbakht K, Shellman YG, Agarwal R, Norris DA, Horwitz LD, Fujita M.

Photochem Photobiol. 2008 Mar-Apr;84(2):477-83. doi: 10.1111/j.1751-1097.2007.00288.x. Epub 2008 Feb 7.

PMID:
18266821
27.

Hyperthermia induces endoplasmic reticulum-mediated apoptosis in melanoma and non-melanoma skin cancer cells.

Shellman YG, Howe WR, Miller LA, Goldstein NB, Pacheco TR, Mahajan RL, LaRue SM, Norris DA.

J Invest Dermatol. 2008 Apr;128(4):949-56. Epub 2007 Nov 8.

28.

Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1.

Riemann H, Takao J, Shellman YG, Hines WA, Edwards CK 3rd, Franzusoff A, Norris DA, Fujita M.

Exp Dermatol. 2007 Oct;16(10):814-22. Erratum in: Exp Dermatol. 2008 Apr;17(4):372. Franzusoff, Alex [added].

PMID:
17845213
29.
30.

RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway.

Ruth MC, Xu Y, Maxwell IH, Ahn NG, Norris DA, Shellman YG.

J Invest Dermatol. 2006 Apr;126(4):862-8.

31.

A simple technique for quantifying apoptosis in 96-well plates.

Ribble D, Goldstein NB, Norris DA, Shellman YG.

BMC Biotechnol. 2005 May 10;5:12.

32.

Lovastatin-induced apoptosis in human melanoma cell lines.

Shellman YG, Ribble D, Miller L, Gendall J, Vanbuskirk K, Kelly D, Norris DA, Dellavalle RP.

Melanoma Res. 2005 Apr;15(2):83-9.

PMID:
15846140
33.

Fast response temperature measurement and highly reproducible heating methods for 96-well plates.

Shellman YG, Ribble D, Yi M, Pacheco T, Hensley M, Finch D, Kreith F, Mahajan RL, Norris DA.

Biotechniques. 2004 Jun;36(6):968-72, 974-6.

34.

Ultraviolet radiation induces release of MIA: a new mechanism for UVR-induced progression of melanoma.

Marr DG, Poser I, Shellman YG, Bosserhoff AK, Norris DA.

Int J Oncol. 2004 Jul;25(1):105-11.

PMID:
15201995
35.
36.

Functional proteomic analysis of melanoma progression.

Bernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, Polvinen K, Everett AD, Fukasawa K, Norris DA, Ahn NG, Resing KA.

Cancer Res. 2003 Oct 15;63(20):6716-25.

37.

Regulation of Fas-mediated apoptosis by N-ras in melanoma.

Urquhart JL, Meech SJ, Marr DG, Shellman YG, Duke RC, Norris DA.

J Invest Dermatol. 2002 Sep;119(3):556-61.

38.

Expression of activated N-ras in a primary melanoma cell line counteracts growth inhibition by transforming growth factor-beta.

Shellman YG, Chapman JT, Fujita M, Norris DA, Maxwell IH.

J Invest Dermatol. 2000 Jun;114(6):1200-4.

39.

Cell cycle control of Cdc7p kinase activity through regulation of Dbf4p stability.

Oshiro G, Owens JC, Shellman Y, Sclafani RA, Li JJ.

Mol Cell Biol. 1999 Jul;19(7):4888-96.

40.
41.

Oligomers of the Cdc7/Dbf4 protein kinase exist in the yeast cell.

Shellman YG, Schauer IE, Oshiro G, Dohrmann P, Sclafani RA.

Mol Gen Genet. 1998 Sep;259(4):429-36.

PMID:
9790600

Supplemental Content

Loading ...
Support Center